ALT News

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

ALT

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.

April 14, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target

ALT

April 3, 2025
Read more →

Citizens Capital Markets Reiterates Market Outperform on Altimmune, Maintains $25 Price Target

ALT

April 2, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target

ALT

March 18, 2025
Read more →

Watching Altimmune; Traders Circulate M&A Blog Comments Suggesting Multiple Large Pharma Co's Interested In The Company

ALT

March 14, 2025
Read more →

Citizens Capital Markets Reiterates Market Outperform on Altimmune, Maintains $25 Price Target

ALT

March 14, 2025
Read more →

Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders

ALT

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.

March 14, 2025
Read more →

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

ALT

March 3, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target

ALT

March 3, 2025
Read more →

This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

ALT

February 28, 2025
Read more →

William Blair Initiates Coverage On Altimmune with Market Perform Rating

ALT

February 28, 2025
Read more →

Altimmune Q4 2024 GAAP EPS $(0.33), Inline, Sales $5.00K Down From $37.00K YoY, Cash, Cash Equivalents And Short-term Investments Of $131.9M

ALT

February 27, 2025
Read more →

Altimmune Will Be Added To The Nasdaq Biotechnology Index Effective Prior To The Market Open On December 23, 2024

ALT

December 19, 2024
Read more →

Altimmune Presents New Data On The Effect Of Pemvidutide On Inflammatory Lipids In Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease At The Liver Meeting 2024

ALT

November 15, 2024
Read more →

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target

ALT

November 14, 2024
Read more →

Dow, S&P 500 Turn Lower; Altimmune Shares Slide

ALT

U.S. stocks pared gains toward the end of trading, with the Dow Jones dropping around 80 points on Wednesday.

September 14, 2022
Read more →

12 Health Care Stocks Moving In Wednesday's Intraday Session

ALT

September 14, 2022
Read more →

Nasdaq Surges 100 Points; Crude Oil Rises 2%

ALT

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Wednesday.

September 14, 2022
Read more →

US Stocks Open Higher, Producer Prices Decline for 2nd Month

ALT

U.S. stocks traded higher this morning, following the release of PPI data for August.

September 14, 2022
Read more →

Altimmune Shares Fall Despite Fatty Liver Disease Study Meets Primary Goal

ALT

September 14, 2022
Read more →

Altimmune Stock Is Tanking: What's Going On?

ALT

Altimmune Inc (NASDAQ: ALT) shares are falling Wednesday morning. The company announced topline results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty liver disease.

September 14, 2022
Read more →

Altimmune Announces 2-Week Phase 1b Clinical Trial Of Pemvidutide In Subjects With NAFLD Achieved Primary Endpoint

ALT

September 14, 2022
Read more →

10 Health Care Stocks Whale Activity In Today's Session

ALT

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

September 13, 2022
Read more →

Altimmune Option Alert: Oct 21 $21 Calls Sweep (32) near the Ask: 372 @ $3.901 vs 1012 OI; Earnings 11/8 After Close [est] Ref=$19.8901

ALT

September 9, 2022
Read more →